VivoSeq
Neurology

Traumatic Brain Injury

3

Pipeline Programs

14

Active Trials

5

Companies Involved

Traumatic Brain Injury is an early-stage landscape with 3 programs across 5 companies. The most active players are Fresenius Kabi Oncology Ltd., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Mario Negri Institute for Pharmacological Research.

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

32/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

18

clinical trials

Recruiting10 · 56%
Completed4 · 22%
Not yet recruiting4 · 22%

Trial Activity

18 trials

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)